Skip to content

Stent-less Treatment Strategy for acute coronary syndrome

Stent-less Treatment Strategy with Scoring Balloon and Drug-coated Balloon for De novo Lesions of Acute Coronary Syndrome - Yokohama DCB study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032240139
Enrollment
30
Registered
2024-06-04
Start date
2024-12-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndrome acute coronary syndrome

Interventions

Combined treatment with scoring balloon and drug-coated balloon
D054058
drug-coated balloon

Sponsors

Hibi Kiyoshi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with acute coronary syndrome who achieved reperfusion of TIMI flow grader than or equal to 2 of the target lesion before or during intracoronary imaging-guided PCI 2) Patients with no significant dissection before enrollment: defined as dissection with no hematoma or media injury with circumferential extent of dissection less than 180 degrees, and no progression over a 15-minute course 3) Patients scheduled for treatment with DES or DCB 4) Patients with a lesions that is expected to be treatable with a single DCB (lesion length less than 30 mm) 5) Patients who are 20 years of age or older at the time consent is obtained 6) Patients whose written consent has been obtained 7) Patients with no disturbance of consciousness (Japan Coma Scale 0) 8) Patients with no history of dementia

Exclusion criteria

Exclusion criteria: 1) Patients whose life expectancy is expected to be less than 1 year 2) Patients with cardiogenic shock at the time of PCI 3) Patients with stent thrombosis lesions or in-stent restenosis lesions 4) Patients with chronic total occlusion lesions, left main trunk lesions, bypass graft lesions, or heavily calcified lesions 5) Female patients who are pregnant or planning to become pregnant or who are breastfeeding 6) Patients allergic to paclitaxel and iopromide 7) Patients allergic to contrast media 8) Patients with severe renal dysfunction (eGFR of less than 30 ml per min per 1.73m2) or dialysis 9) Patients with lesions with a vessel diameter greater than 4.5 mm 10) Patients who are deemed inappropriate as subjects by the principal investigator or subinvestigator 11) Patients participating in the other clinical trials or clinical studies 12) Patients with allergies or adverse reactions to antithrombotic drugs 13) Patients who do not receive a clear response about their participation

Design outcomes

Primary

MeasureTime frame
Percentage of successful treatment without stenting by interventional treatment

Secondary

MeasureTime frame
- Quantitative flow ratio value at the end of PCI - Minimum lumen area - Degree of dissection - Quantitative angiography - Major cardiovascular events within 30 days of PCI - Major cardiovascular events within 1 year of PCI

Contacts

Public ContactKozo Okada

Yokohama City University Medcial Center

kokada2@yokohama-cu.ac.jp+81-45-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026